Advertisement

The effect of major postoperative complications on recurrence and long-term survival after cytoreductive surgery for ovarian cancer

      Highlights

      • Major surgical complications have a negative impact on patients' disease-free survival
      • Major postoperative complications hinder the delivery of adjuvant chemotherapy
      • Extensive peritonectomy and surgical timing are linked to major postoperative morbidity

      Abstract

      Objective

      To assess the impact on survival of major postoperative complications and to identify the factors associated with these complications in patients with advanced ovarian cancer after cytoreductive surgery.

      Methods

      We designed a retrospective multicenter study collecting data from patients with IIIC-IV FIGO Stage ovarian cancer who had undergone either primary debulking surgery (PDS), early interval debulking surgery (IDS) after 3–4 cycles of neoadjuvant chemotherapy, or delayed debulking surgery (DDS) after 6 cycles, with minimal or no residual disease, from January 2008 to December 2015. Univariable and multivariable analyses were conducted to identify factors associated with major surgical complications (≥Grade 3). We assessed disease-free survival (DFS) and overall survival (OS) rates according to the occurrence of major postoperative complications.

      Results

      549 women were included. The overall rate of major surgical complications was 22.4%. Patients who underwent PDS had a higher rate of major complications (28.6%) than patients who underwent either early IDS (23.2%) or DDS (14.0%). Multivariable analysis revealed that extensive peritonectomy and surgical timing were associated with the occurrence of major complications. Median DFS and OS were 16.9 months (95%CI = [13.7–18.4]) and 48.0 months (95%CI = [37.2–73.1]) for the group of patients with major complications, and 20.1 months (95%CI = [18.6–22.4]) and 56.7 months (95%CI = [51.2–70.4]) for the group without major complications. Multivariable analysis revealed that major surgical complications were significantly associated with DFS, but not with OS.

      Conclusions

      Patients who experienced major surgical complications had reduced DFS, compared with patients without major morbidity. Extensive peritonectomy and surgical timing were predictive factors of postoperative morbidity.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Chi D.S.
        • Eisenhauer E.L.
        • Lang J.
        • Huh J.
        • Haddad L.
        • Abu-Rustum N.R.
        • Sonoda Y.
        • Levine D.A.
        • Hensley M.
        • Barakat R.R.
        What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?.
        Gynecol. Oncol. 2006; 103: 559-564https://doi.org/10.1016/j.ygyno.2006.03.051
        • Bristow R.E.
        • Tomacruz R.S.
        • Armstrong D.K.
        • Trimble E.L.
        • Montz F.J.
        Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.
        J. Clin. Oncol. 2002; 20: 1248-1259https://doi.org/10.1200/JCO.2002.20.5.1248
        • Ozols R.F.
        • Bundy B.N.
        • Greer B.E.
        • Fowler J.M.
        • Clarke-Pearson D.
        • Burger R.A.
        • Mannel R.S.
        • DeGeest K.
        • Hartenbach E.M.
        • Baergen R.
        • Mackey D.
        Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study.
        J. Clin. Oncol. 2003; 21: 3194-3200https://doi.org/10.1200/JCO.2003.02.153
        • Chiva L.
        • Lapuente F.
        • Castellanos T.
        • Alonso S.
        • Gonzalez-Martin A.
        What should we expect after a complete cytoreduction at the time of interval or primary debulking surgery in advanced ovarian cancer?.
        Ann. Surg. Oncol. 2016; 23: 1666-1673https://doi.org/10.1245/s10434-015-5051-9
        • Chi D.S.
        • Eisenhauer E.L.
        • Zivanovic O.
        • Sonoda Y.
        • Abu-Rustum N.R.
        • Levine D.A.
        • Guile M.W.
        • Bristow R.E.
        • Aghajanian C.
        • Barakat R.R.
        Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm.
        Gynecol. Oncol. 2009; 114: 26-31https://doi.org/10.1016/j.ygyno.2009.03.018
        • Liberale G.
        • Pop C.-F.
        • Polastro L.
        • Kerger J.
        • Moreau M.
        • Chintinne M.
        • Larsimont D.
        • Nogaret J.M.
        • Veys I.
        A radical approach to achieve complete cytoreductive surgery improve survival of patients with advanced ovarian cancer.
        J. Visc. Surg. 2020; 157: 79-86https://doi.org/10.1016/j.jviscsurg.2019.12.002
        • Chi D.S.
        • Zivanovic O.
        • Levinson K.L.
        • Kolev V.
        • Huh J.
        • Dottino J.
        • Gardner G.J.
        • Leitao M.M.
        • Levine D.A.
        • Sonoda Y.
        • Abu-Rustum N.R.
        • Brown C.L.
        • Barakat R.R.
        The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas.
        Gynecol. Oncol. 2010; 119: 38-42https://doi.org/10.1016/j.ygyno.2010.05.031
        • Gerestein C.G.
        • Damhuis R.A.M.
        • Burger C.W.
        • Kooi G.S.
        Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: a systematic review.
        Gynecol. Oncol. 2009; 114: 523-527https://doi.org/10.1016/j.ygyno.2009.03.011
        • Aletti G.D.
        • Dowdy S.C.
        • Podratz K.C.
        • Cliby W.A.
        Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer.
        Am. J. Obstet. Gynecol. 2007; 197: e1-676.e7https://doi.org/10.1016/j.ajog.2007.10.495
        • Wright A.A.
        • Bohlke K.
        • Armstrong D.K.
        • Bookman M.A.
        • Cliby W.A.
        • Coleman R.L.
        • Dizon D.S.
        • Kash J.J.
        • Meyer L.A.
        • Moore K.N.
        • Olawaiye A.B.
        • Oldham J.
        • Salani R.
        • Sparacio D.
        • Tew W.P.
        • Vergote I.
        • Edelson M.I.
        Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of clinical oncology clinical practice guideline.
        J. Clin. Oncol. 2016; 34: 3460-3473https://doi.org/10.1097/CCM.0b013e31823da96d.Hydrogen
        • Bartels H.C.
        • Rogers A.C.
        • McSharry V.
        • McVey R.
        • Walsh T.
        • O’Brien D.
        • Boyd W.D.
        • Brennan D.J.
        A meta-analysis of morbidity and mortality in primary cytoreductive surgery compared to neoadjuvant chemotherapy in advanced ovarian malignancy.
        Gynecol. Oncol. 2019; 154: 622-630https://doi.org/10.1016/j.ygyno.2019.07.011
        • Yoneoka Y.
        • Ishikawa M.
        • Uehara T.
        • Shimizu H.
        • Uno M.
        • Murakami T.
        • Kato T.
        Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?.
        J. Gynecol. Oncol. 2019; 30: 1-10https://doi.org/10.3802/jgo.2019.30.e81
        • Akladios C.
        • Baldauf J.
        • Marchal F.
        • Hummel M.
        • Rebstock L.-E.
        • Kurtz J.-E.
        • Petit T.
        • Afors K.
        • Mathelin C.
        • Lecointre L.
        • Schrot-Sanyan S.
        Does the number of neoadjuvant chemotherapy cycles before interval debulking surgery influence survival in advanced ovarian cancer?.
        Oncology. 2016; 91: 331-340https://doi.org/10.1159/000449203
        • Phillips A.
        • Sundar S.
        • Singh K.
        • Nevin J.
        • Elattar A.
        • Kehoe S.
        • Balega J.
        Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer.
        Eur. J. Surg. Oncol. 2018; 44: 760-765https://doi.org/10.1016/j.ejso.2018.01.097
        • Stoeckle E.
        • Boubli B.
        • Floquet A.
        • Brouste V.
        • Sire M.
        • Croce S.
        • Thomas L.
        • Guyon F.
        Optimal timing of interval debulking surgery in advanced ovarian cancer: yet to be defined?.
        Eur. J. Obstet. Gynecol. Reprod. Biol. 2011; 159: 407-412https://doi.org/10.1016/j.ejogrb.2011.07.014
        • Lomnytska M.
        • Karlsson E.
        • Jonsdottir B.
        • Lejon A.-M.
        • Stålberg K.
        • Poromaa I.S.
        • Silins I.
        • Graf W.
        Peritoneal cancer index predicts severe complications after ovarian cancer surgery.
        Eur. J. Surg. Oncol. 2021; https://doi.org/10.1016/j.ejso.2021.05.019
        • Wright J.D.
        • Herzog T.J.
        • Neugut A.I.
        • Burke W.M.
        • Lu Y.-S.
        • Lewin S.N.
        • Hershman D.L.
        Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stage ovarian cancer.
        Obstet. Gynecol. 2012; 120: 871-881https://doi.org/10.1097/AOG.0b013e31826981de
        • Baratti D.
        • Kusamura S.
        • Iusco D.
        • Bonomi S.
        • Grassi A.
        • Virz S.
        • Leo E.
        • Deraco M.
        Postoperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy affect long-term outcome of patients with peritoneal metastases from colorectal cancer: a two-center study of 101 patients.
        Dis. Colon Rectum. 2014; 57: 858-868https://doi.org/10.1097/DCR.0000000000000149
        • Simkens G.A.
        • van Oudheusden T.R.
        • Luyer M.D.
        • Nienhuijs S.W.
        • Nieuwenhuijzen G.A.
        • Rutten H.J.
        • de Hingh I.H.
        Serious postoperative complications affect early recurrence after cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis.
        Ann. Surg. Oncol. 2015; 22: 2656-2662https://doi.org/10.1245/s10434-014-4297-y
        • Sugarbaker P.H.
        Peritonectomy procedures.
        Ann. Surg. 1995; 221: 29-42https://doi.org/10.1097/00000658-199501000-00004
        • Gilly F.N.
        • Cotte E.
        • Brigand C.
        • Monneuse O.
        • Beaujard A.C.
        • Freyer G.
        • Glehen O.
        Quantitative prognostic indices in peritoneal carcinomatosis.
        Eur. J. Surg. Oncol. 2006; 32: 597-601https://doi.org/10.1016/j.ejso.2006.03.002
        • Harter P.
        • Sehouli J.
        • Lorusso D.
        • Reuss A.
        • Vergote I.
        • Marth C.
        • Kim J.-W.
        • Raspagliesi F.
        • Lampe B.
        • Aletti G.
        • Meier W.
        • Cibula D.
        • Mustea A.
        • Mahner S.
        • Runnebaum I.B.
        • Schmalfeldt B.
        • Burges A.
        • Kimmig R.
        • Scambia G.
        • Greggi S.
        • Hilpert F.
        • Hasenburg A.
        • Hillemanns P.
        • Giorda G.
        • von Leffern I.
        • Schade-Brittinger C.
        • Wagner U.
        • du Bois A.
        A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms.
        N. Engl. J. Med. 2019; 380: 822-832https://doi.org/10.1056/NEJMoa1808424
        • Aletti G.D.
        • Santillan A.
        • Eisenhauer E.L.
        • Hu J.
        • Aletti G.
        • Podratz K.C.
        • Bristow R.E.
        • Chi D.S.
        • Cliby W.A.
        A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model.
        Gynecol. Oncol. 2007; 107: 99-106https://doi.org/10.1016/j.ygyno.2007.05.032
        • Dindo D.
        • Demartines N.
        • Clavien P.A.
        Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.
        Ann. Surg. 2004; 240: 205-213https://doi.org/10.1097/01.sla.0000133083.54934.ae
        • Patankar S.
        • Burke W.M.
        • Hou J.Y.
        • Tergas A.I.
        • Huang Y.
        • Ananth C.V.
        • Neugut A.I.
        • Hershman D.L.
        • Wright J.D.
        Risk stratification and outcomes of women undergoing surgery for ovarian cancer.
        Gynecol. Oncol. 2015; 138: 62-69https://doi.org/10.1016/j.ygyno.2015.04.037
        • Fagotti A.
        • Ferrandina G.
        • Vizzielli G.
        • Fanfani F.
        • Gallotta V.
        • Chiantera V.
        • Costantini B.
        • Margariti P.A.
        • Gueli Alletti S.
        • Cosentino F.
        • Tortorella L.
        • Scambia G.
        Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome.
        Eur. J. Cancer. 2016; 59: 22-33https://doi.org/10.1016/j.ejca.2016.01.017
        • Di Donato V.
        • Di Pinto A.
        • Giannini A.
        • Caruso G.
        • D’Oria O.
        • Tomao F.
        • Fischetti M.
        • Perniola G.
        • Palaia I.
        • Muzii L.
        • Benedetti Panici P.
        Modified fragility index and surgical complexity score are able to predict postoperative morbidity and mortality after cytoreductive surgery for advanced ovarian cancer.
        Gynecol. Oncol. 2021; 161: 4-10https://doi.org/10.1016/j.ygyno.2020.08.022
        • Schoenfeld D.A.
        • Finkelstein D.M.
        Assessing survival benefit when treatment delays disease progression.
        Clin. Trials. 2016; 13: 352-357https://doi.org/10.1177/1740774515625990
        • Koscielny A.
        • Ko A.
        • Egger E.K.
        • Kuhn W.
        • Kalff J.C.
        • Keyver-Paik M.D.
        Prevention of anastomotic leakage in ovarian cancer debulking surgery and its impact on overall survival.
        Anticancer Res. 2019; 39: 5209-5218https://doi.org/10.21873/anticanres.13718
        • Choudry M.H.A.
        • Shuai Y.
        • Jones H.L.
        • Pai R.K.
        • Pingpank J.F.
        • Ahrendt S.S.
        • Holtzman M.P.
        • Zeh H.J.
        • Bartlett D.L.
        Postoperative complications independently predict cancer-related survival in peritoneal malignancies.
        Ann. Surg. Oncol. 2018; 25: 3950-3959https://doi.org/10.1245/s10434-018-6823-9
        • Pachot A.
        • Cazalis M.-A.
        • Venet F.
        • Turrel F.
        • Faudot C.
        • Voirin N.
        • Diasparra J.
        • Bourgoin N.
        • Poitevin F.
        • Mougin B.
        • Lepape A.
        • Monneret G.
        Decreased expression of the fractalkine receptor CX3CR1 on circulating monocytes as new feature of sepsis-induced immunosuppression.
        J. Immunol. 2008; 180: 6421-6429https://doi.org/10.4049/jimmunol.180.9.6421
        • Mantovani A.
        • Allavena P.
        • Sica A.
        • Balkwill F.
        Cancer-related inflammation.
        Nature. 2008; 454: 436-444https://doi.org/10.1038/nature07205
        • McSorley S.T.
        • Horgan P.G.
        • McMillan D.C.
        The impact of preoperative corticosteroids on the systemic inflammatory response and postoperative complications following surgery for gastrointestinal cancer: a systematic review and meta-analysis.
        Crit. Rev. Oncol. Hematol. 2016; 101: 139-150https://doi.org/10.1016/j.critrevonc.2016.03.011
        • Grivennikov S.I.
        • Greten F.R.
        • Karin M.
        Immunity, inflammation, and cancer.
        Cell. 2010; 140: 883-899https://doi.org/10.1016/j.cell.2010.01.025.Immunity
        • Alonso S.
        • Pascual M.
        • Salvans S.
        • Mayol X.
        • Mojal S.
        • Gil M.J.
        • Grande L.
        • Pera M.
        Postoperative intra-abdominal infection and colorectal cancer recurrence: a prospective matched cohort study of inflammatory and angiogenic responses as mechanisms involved in this association.
        Eur. J. Surg. Oncol. 2015; 41: 208-214https://doi.org/10.1016/j.ejso.2014.10.052
        • Singh S.
        • Guetzko M.
        • Resnick K.
        Preoperative predictors of delay in initiation of adjuvant chemotherapy in patients undergoing primary debulking surgery for ovarian cancer.
        Gynecol. Oncol. 2016; 143: 241-245https://doi.org/10.1016/j.ygyno.2016.09.004
        • Raspé C.
        • Flöther L.
        • Schneider R.
        • Bucher M.
        • Piso P.
        Best practice for perioperative management of patients with cytoreductive surgery and HIPEC.
        Eur. J. Surg. Oncol. 2017; 43: 1013-1027https://doi.org/10.1016/j.ejso.2016.09.008